106401-68-7 Usage
Description
Doxorubicin IMpurity B, also known as (8S,10S)-10-[(3-Amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-8-(2-bromo-1,1-dimethoxyethyl)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione, is a metabolite of Doxorubicin (D558000). It is a neoplasm inhibitor and an impurity found in the production of Doxorubicin, a widely used chemotherapy drug.
Uses
Used in Pharmaceutical Industry:
Doxorubicin IMpurity B is used as an impurity in the production of Doxorubicin, which is an anticancer agent. It is important to monitor and control the levels of this impurity to ensure the safety and efficacy of the final drug product.
Used in Research and Development:
Doxorubicin IMpurity B is used as a research compound for studying the properties and effects of Doxorubicin and its metabolites. This can help in understanding the drug's mechanism of action, potential side effects, and ways to improve its therapeutic index.
Used in Quality Control:
Doxorubicin IMpurity B is used in quality control processes to ensure that the final Doxorubicin product meets the required standards for purity and potency. This is crucial for maintaining the safety and effectiveness of the drug for patients.
Used in Drug Development:
Doxorubicin IMpurity B can be used in the development of new drugs or drug formulations that may have improved properties compared to the parent compound, Doxorubicin. This can include efforts to reduce side effects, improve solubility, or enhance the drug's ability to target cancer cells specifically.
Used in Antimicrobial Applications:
Doxorubicin Ketal Derivative, which is related to Doxorubicin IMpurity B, has been identified as an antibacterial compound. This suggests that further research into the properties of Doxorubicin IMpurity B and its derivatives could potentially lead to the development of new antimicrobial agents to combat bacterial infections.
Check Digit Verification of cas no
The CAS Registry Mumber 106401-68-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,6,4,0 and 1 respectively; the second part has 2 digits, 6 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 106401-68:
(8*1)+(7*0)+(6*6)+(5*4)+(4*0)+(3*1)+(2*6)+(1*8)=87
87 % 10 = 7
So 106401-68-7 is a valid CAS Registry Number.
106401-68-7Relevant articles and documents
Improved therapeutic efficacy of doxorubicin through conjugation with a novel peptide drug delivery technology (Vectocell)
Meyer-Losic, Florence,Quinonero, Jér?me,Dubois, Vincent,Alluis, Bertrand,Dechambre, Mireille,Michel, Matthieu,Cailler, Fran?oise,Fernandez, Anne-Marie,Trouet, André,Kearsey, Jonathan
, p. 6908 - 6916 (2006)
Improvement in the therapeutic index of doxorubicin, a cytotoxic molecule, has been sought through its chemical conjugation to short (15-23 amino acid) peptide sequences called Vectocell peptides. Vectocell peptides are highly charged drug delivery peptides and display a number of characteristics that make them attractive candidates to minimize many of the limitations observed for a broad range of cytotoxic molecules. The studies reported here characterized the in vitro and in vivo efficacy of a range of Vectocell peptides conjugated to doxorubicin through different linkers. These studies show that the in vivo therapeutic index of doxorubicin can be improved by conjugation with a specific Vectocell peptide (DPV 1047) through an ester linker to C14 of doxorubicin, in both colon and breast tumor models. This conjugate was also shown to have significant in vivo antitumoral activity in a model resistant to doxorubicin, suggesting that this conjugate is able to circumvent the multidrug resistance (MDR) phenotype. These experiments therefore provide support for the use of the Vectocell technology with other cytotoxic agents.
Synthesis and antitumor activity of new D-galactose-containing derivatives of doxorubicin
Olsufyeva, Eugenia N.,Tevyashova, Anna N.,Trestchalin, Ivan D.,Preobrazhenskaya, Maria N.,Platt, David,Klyosov, Anatole
, p. 1359 - 1367 (2007/10/03)
A general scheme of synthesis of antibiotic doxorubicin derivatives is based on the 13-dimethyl ketal of 14-bromodaunorubicin (4). The interaction of 4 with melibiose (5), lactose (6), 3-methoxy-4-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-4- oxybenz
